Iodine Uptake After a Low Iodine Diet
Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Oct 25, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a low iodine diet (LID) affects the way the thyroid absorbs iodine in patients with differentiated thyroid cancer (DTC). Specifically, the researchers want to see the difference in iodine uptake before and after participants follow a 7-day low iodine diet, using a low dose of radioactive iodine for measurement. This information is important because it helps doctors understand how effective the diet is in preparing patients for further treatment, such as radioactive iodine therapy.
To participate in this trial, individuals must be at least 18 years old, diagnosed with differentiated thyroid cancer, and able to follow the study guidelines. They also need to be able to understand Dutch. Some people may not be eligible, such as those under 18, those taking certain medications, or those with kidney problems. If you join the study, you can expect to follow the low iodine diet for a week and then have your iodine uptake measured before and after this diet. This research is currently recruiting participants and aims to gather valuable insights for better treatment strategies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients, men and women above the age of 18 years, have to be diagnosed with DTC and have to follow a LID prior to the 131I ablation therapy according to the Dutch DTC guideline
- • Patients have to be fit to adhere to the study protocol
- • Patients have to be able to read and understand the Dutch language
- Exclusion Criteria:
- • Age \< 18 years
- • Patients using amiodarone
- • Patients receiving iodinated contrast \< 3 months before the LID
- • Pregnancy
- • Patients prepared for ablation therapy with rhTSH
- • Renal impairment, EGFR \<30ml/min/1,73m2
About University Medical Center Groningen
University Medical Center Groningen (UMCG) is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and extensive education in the medical field. As a prominent sponsor of clinical trials, UMCG leverages its multidisciplinary expertise and state-of-the-art facilities to advance medical knowledge and improve therapeutic outcomes. The center fosters collaboration among researchers, healthcare professionals, and industry partners, aiming to translate scientific discoveries into effective treatments that enhance patient health and well-being. With a focus on ethical standards and regulatory compliance, UMCG is dedicated to conducting clinical trials that contribute to the advancement of medicine and the betterment of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Groningen, , Netherlands
Patients applied
Trial Officials
Wouter Zandee, Dr.
Principal Investigator
University Medical Center Groningen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials